Zoldonrasib and daraxonrasib versus chemotherapy for first treatment of metastatic KRAS G12D pancreatic cancer
Compares zoldonrasib with daraxonrasib against chemotherapy in newly treated metastatic KRAS G12D pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Key facts
- Where
- Jacksonville, Phoenix, Providence, Rochester, Scottsdale, and Tampa, United StatesSee the 6 sites
- Phase
- Phase 3
Where in United States
- Mayo Clinic FloridaJacksonville, United StatesTaking people
- Mayo Clinic - ArizonaPhoenix, United StatesTaking people
- Rhode Island HospitalProvidence, United StatesTaking people
- Mayo Clinic - RochesterRochester, United StatesTaking people
- HonorHealth Research InstituteScottsdale, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT07805954
- Record updated
- 6 November 2026
- Original description
The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.Read full original descriptionShow less
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.
Inclusion: At least 18 years old and has provided informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Histologically or cytologically confirmed pancreatic adenocarcinoma, including adenosquamous carcinoma, not previously treated in the locally advanced unresectable or metastatic setting; No prior treatment in the locally advanced unresectable or metastatic setting; Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent; Documented KRAS G12D mutation status; Measurable disease per RECIST v1.1; Adequate organ function (bone marrow, liver, kidney, coagulation).
Exclusion: Mutation status with known driver mutations for which there are approved targeted therapies; Prior treatment with MAPK-pathway targeted therapy or administration of RAS-targeted vaccine in the metastatic setting; Major surgery within 28 days prior to randomization; Acinar cell carcinoma, pancreatic neuroendocrine tumors, tumors involving islet cells or islet cell neoplasms, and other non-adenocarcinoma pancreatic malignancies; Active or known history of untreated central nervous system metastatic or leptomeningeal disease; Any conditions that may affect the ability to take or absorb study drug; Tumors determined to originate from non-pancreatic primary sites; Patient is unable or unwilling to comply with protocol-required study visits or procedures; Additional inclusion \& exclusion criteria may apply.